AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA
… against a key Axiomer patent protecting ADAR-mediated RNA editing Well-capitalized with €139 M, in cash and cash … defense of a key Axiomer patent protecting ADAR-mediated RNA editing. The oppositions were filed in February 2021 with …
… to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple … Agency (EMA) and US Food and Drug Administration (FDA) RNA editing technology – Accelerate development of the …